10-Q quarterly report · filed Nov 12, 2026

Monopar Therapeutics (MNPR) Q3 2026 10-Q Quarterly Report

Short answer

Monopar Therapeutics (MNPR) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$6M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$6M
−80.3% YoY · −16.6% QoQ
EPS (diluted)
−$0.72
−50.0% YoY · −16.1% QoQ

Source: XBRL data from the Monopar Therapeutics (MNPR) Q3 2026 10-Q on SEC EDGAR. USD.

Monopar Therapeutics Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no approved drugs or product sales
  • Net loss $6.2M vs $3.4M YoY, operating loss $7.5M vs $4.1M
  • R&D expense $4.4M vs $2.6M YoY, G&A expense $3.0M vs $1.5M
  • Cash, equivalents and investments $129.4M as of September 30, 2026
  • Operating cash outflow $12.9M vs $9.1M YoY, funds expected through March 31, 2028; NDA rolling submission completion anticipated within several weeks

Risk Factors

  • New regulatory risk: rolling ALXN1840 NDA submission and review, with potential U.S. government shutdown delays
  • Most material program change: Alexion terminated ALXN1840 Wilson disease development after Phase 2 review and regulator discussions
  • Operational risk: radiopharmaceutical programs depend on adequate radioisotope supply and time-limited product shelf life
  • Market risk: larger competitors possess greater capital, organizational, marketing and sales resources
  • Financial risk: $104.9 million accumulated deficit, with operations funded through March 31, 2028 by current cash and investments

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Monopar Therapeutics quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.